Tag Archives: exas

Exact Sciences Soars As Test Gets National Coverage

Shares of biotech Exact Sciences (EXAS) vaulted more than 45% to a new high in early trading on the stock market today after the federal government agreed to reimburse its new colon-cancer test at the rate the company requested. By late morning, Exact Sciences stock was up 33%, near 24. As recently described in a Q&A with CEO Kevin Conroy, Cologuard, the first non-invasive DNA screening test for colon cancer, was approved in August. At the same

Exact Sciences Colon Cancer Test Awaits The Money Man

For a biotech startup, getting a product approved is the main hurdle. But then the company faces another one: getting paid. That’s where Exact Sciences (EXAS) finds itself. On Aug. 11, the FDA approved Cologuard, an innovative, noninvasive DNA screening test for colon cancer. Since doctors recommend colon screening for people over 50, Medicare figures to be a major payer for Cologuard. Exact Sciences is still waiting for the Center for Medicare &